Because the EU’s 27 member states scramble to comprise the unfold of latest “mutant” strains of the Covid-19 virus, the top of the European Medicines Company, Emer Cooke, tells FRANCE 24 that there are “promising” outcomes from early research into how nicely present vaccines work towards the brand new variants. The so-called “UK variant”, in any other case often known as pressure B.1.1.7, transmits extra simply from individual to individual and there are predictions that it’s going to turn out to be the dominant pressure inside weeks.
EMA Govt Director Emer Cooke says that ongoing preliminary research look “promising” – and that the EMA has requested vaccine producers to plan research to show their outcomes “conclusively”.
In the meantime, a rising record of European states are casting doubt on the efficacy, in people aged over 65, of the vaccine developed by Oxford College and AstraZeneca – one of many three authorised vaccines within the EU.
Well being authorities in France, Germany, Italy, the Netherlands and Sweden have all beneficial the jab solely be utilized in adults aged as much as 65.
When requested whether or not the Oxford/AstraZeneca jab is secure in over-65s, Cooke tells FRANCE 24: “We have seemed on the immunity challenge throughout totally different age teams – and the security points, as a result of the security profiles have been checked out in adults over 65. And we do not see a motive to say it shouldn’t be beneficial for adults over 65.”
The EMA head additionally tackles vaccine hesitancy and the questions of how the vaccines have been developed so rapidly, and whether or not they’re secure – underlining that “the processes which were adopted are the usual processes for any vaccine”.
“It is essential to keep in mind that there was an infinite quantity of multi-stakeholder engagement to actually mobilise the processes essential to focus in on the virus, to do the event course of, to guarantee that manufacturing capability was obtainable. And we now have very, very massive knowledge units… Which provides you an excellent understanding of the efficacy and security within the populations,” she explains.
Produced by Isabelle Romero and Perrine Desplats